A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), Or Post-Essential Thrombocythemia MF (Post-ET MF)
Latest Information Update: 23 Jan 2024
At a glance
- Drugs Zinpentraxin alfa (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Sponsors Promedior; Roche
- 12 Dec 2023 Results of robust quantitative methods, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 25 Aug 2020 Status changed from active, no longer recruiting to completed.
- 13 Feb 2020 According to a Promedior media release, the Promedior has been acquired and merger with Roche.